1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > World ADME-Toxicology Testing Industry

World ADME-Toxicology Testing Industry

  • February 2015
  • -
  • Global Industry Analysts
  • -
  • 269 pages

This report analyzes the worldwide markets for ADME-Toxicology Testing in US$ Million by the following Segments: Toxicology Testing (In-Vivo, & In-Vitro), and ADME Testing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 73 companies including many key and niche players such as -

ACEA Biosciences, Inc.
ADMEcell, Inc.
Agilent Technologies, Inc.
Albany Molecular Research, Inc.
Bayer Technology Services GmbH

Table Of Contents

World ADME-Toxicology Testing Industry



I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-2
Product Definitions and Scope of Study I-3
ADME-Tox - An Introduction I-3
Toxicology Testing I-3
ADME Testing I-3


II. EXECUTIVE SUMMARY

1. OUTLOOK II-1
ADME-Tox Testing Gains Traction II-1
A Peek into the Impact of ADME-Tox Screening on New Drug
Discovery II-1
Table 1: Phase-I Clinical Trial Failures Before and After the
Advent of Preclinical ADME/Pharmacokinetics (includes
corresponding Graph/Chart) II-2

Table 2: Factors Leading to Failure of Drugs in Phase II
Clinical Trials: Percentage Breakdown of Number of Cases for
Efficacy, Pharmacokinetics, Toxicity and Others (includes
corresponding Graph/Chart) II-3

Table 3: Factors Leading to Failure of Drugs in Phase III
Clinical Trials: Percentage Breakdown of Number of Cases for
Efficacy, Pharmacokinetics, Toxicity and Others (includes
corresponding Graph/Chart) II-3

Table 4: Drug Withdrawals Due to Toxicity Issues (1990-2010):
Percentage Share Breakdown of Number of Drugs Withdrawn Due
to Cardiotoxicity, Hepatotoxicity and Others (includes
corresponding Graph/Chart) II-3
Current and Future Analysis II-4
US and Europe Dominate, Asia-Pacific Lends Growth Momentum II-4
Growth Momentum Shifts Away from In Vivo Technologies; In
Vitro Technologies to Lead the Charge II-4

2. INDUSTRY OVERVIEW II-6
Pharma Industry Renews Focus on Cost Optimization II-6
Table 5: US RandD Productivity Trends in Pharma Industry (2006-
2013) (includes corresponding Graph/Chart) II-6
China and India: Hot Spots for RandD Investment II-7
Table 6: Percentage Breakup of Global RandD Spending by Region
(2012) (includes corresponding Graph/Chart) II-7
ADME-Tox Assays - An Overview II-7
Introduction of Early In Vitro ADMET Studies II-8
Growing Prominence of Cell-based Assays in DrugDiscovery and
ADME Analysis II-8
Table 7: Global Market for Cell-based Assays by Application
(2013): Percentage Breakdown of Value Sales for ADME
Analysis, Basic Research, Drug Discovery, Predictive
Toxicology and Others (includes corresponding Graph/Chart) II-10

Table 8: Global Market for Cell-based Assays (2013):
Percentage Breakdown of Value Sales by Segment (includes
corresponding Graph/Chart) II-10

Table 9: Global Market for Cell-based Assays (2013):
Percentage Breakdown of Value Sales by End-User (includes
corresponding Graph/Chart) II-10
Major Types of Cell-Based HTS Assays for Drug Screening II-11
CROs Expand Presence II-11
Drug Discovery Outsourcing and Type of Services Outsourced II-12
MandA - Order of the Day II-12

3. MARKET DYNAMICS II-13
Focus Shifts to Innovative Approaches II-13
Need for Better Models: A Major Factor Driving Innovation in
the Market II-13
In Silico and In Vitro- the Way to Go II-14
In Vitro Testing Systems and Its Relevance in Drug Development II-14
Growing Inclination towards In-vitro Assays for Toxicology
Studies II-15
In Silico ADME-Tox Growing at a Fast Clip II-15
Advantages of Using In Silico Approaches II-16
Factors Hindering Growth II-16
3-D Tissue Bioassays to Enhance In Vitro Toxicity Testing II-16
3D Printed Organ Tissues for Toxicology Testing: On the Horizon II-16
Increasing Use of Cell-Based Assays over Other Methods in
Toxicity Testing II-17
Rising Number of Drug Targets Surge Demand for Cell-Based Assays II-17
Growing Focus on the Development of Reproducible and Robust
Cell-based Assays II-17
Functional Assays: An Effective Way of Predicting Specific
Toxic Effects II-18
GPCR Targets to Drive Growth in Functional Cell Assay Market II-18
New Alternatives for Early-Stage Toxicology Testing II-18
Stem Cells Exude Great Potential in Drug Toxicity Testing II-19
Primary Hepatocytes Become Standard Tool for Evaluation in
Hepatic Metabolism II-20
Cryopreserved Human Hepatocytes- The Current Buzzword in the
Industry II-20
Cardiotoxicity Testing Gains Prominence II-20
Cell Imaging-Gaining Popularity II-21
Computational Models on Rise II-21
Adoption of Data Management Systems II-21
Drug Transporter Analysis Becoming Part of ADME Assessment II-22
Regulatory Bodies Focus on Transporter Mediated DDIs II-22

4. DRUG DISCOVERY and DEVELOPMENT II-23
Overview II-23
Table 10: Escalating Costs of New Drug Development Over the
Decades (includes corresponding Graph/Chart) II-23
Drug Discovery and Development II-24
Target identification II-24
Target Validation II-24
Lead Identification II-25
Lead Optimization II-25
Pharmaceuticals - RandD Value Chain II-25
Pre-Clinical Testing II-25
Clinical Trials II-26
Clinical Trials - The Time Line II-26
Drug Discovery Technologies II-26
Innovation in Screening Guarantees Success for Drug Discovery
Programs II-27

5. PRODUCT OVERVIEW II-28
ADME-Tox - An Introduction II-28
Absorption II-28
Distribution II-28
Metabolism II-28
Excretion II-28
Toxicity II-29
ADME-Tox Profiling II-29
ADME-Tox Screening Technologies II-29
ADME-Tox Parameters II-30
Cell Based Assays II-30
Liver Cell Based Assays II-31
Intestinal Cell Based Assays II-31
Kidney Cell Based Assays II-31

6. PRODUCT INNOVATIONS/INTRODUCTIONS II-32
BioReliance® Unveils Select In Vitro ADME and Toxicology
Testing Services II-32
Cyprotex Releases SenCeeTox® Technology with Enhanced
Capabilities II-32
Cyprotex Expands In-House Drug Transporter Services II-32
Cyprotex Launches KeratinoSensâ„¢ Service II-32
Simulations Plus Introduces ADMET Predictor Version 7.1 II-32
Lena Biosciences Launches SeedEZ 3D Cell Culture Products II-32
Sigma® Life Science to Introduce Genetically- Modified HepaRG™
Human Liver Cell Line II-32
Hepregen Introduces First Rat Hepatopacâ„¢ DMPK Assay Kits II-33
Hepregen Introduces Human HepatoPacâ„¢ Kit for Metabolite
Identification and Profiling II-33
Hepregen Unveils First Human Hepatopacâ„¢ Assay Kit for
Toxicology Applications II-33
Hurel Introduces Cell-Based In Vitro Testing Product Suite II-33
Plexpress Rolls Out TRACPACK DOG INDUCTION ADMET Service for
Canine II-33
Simulations Plus Rolls Out New Version of ADMET Predictorâ„¢
Software Program II-33
Cyprotex Introduces eCiphrCardio for Cardiotoxicity Services II-33
Cyprotex Introduces New CellCiphr® Premier II-34
Simulations Plus Introduces New Version of ADMET Predictorâ„¢ II-34
Cyprotex and InSphero Unveil New Liver Toxicology Screening
Service II-34
Cyprotex Unveils PXR/AhR Nuclear Receptor Activation Assay and
Lysosomotropism Service II-34
Celerion Expands ADME Suite II-34
Plexpress Extends Pre-Validated Probe Line under TRAC System II-34

7. RECENT INDUSTRY ACTIVITY II-35
Takara Bio Acquires Cellectis AB II-35
WuXi PharmaTech Acquires XenoBiotic Laboratories II-35
Merck KGaA to Take Over Sigma-Aldrich II-35
Dassault Systemes Acquires Accelrys II-35
Organovo Collaborates with JandJ for 3D Bioprinting Drug
Discovery Research II-35
Taconic and IVAL Enter into Agreement II-35
Charles River to Acquire Galapagos' Argenta and BioFocus
Service Divisions II-35
Simulations Plus Signs 5-Year RCA with the US FDA II-36
Simulation Plus Inks Distributor Agreement with RILD II-36
Harlan CRS Enters into Strategic Alliance with Bertin Pharma II-36
Pharmaron Receives GLP Certification from the CFDA for GLP
Toxicology Facilities II-36
Cyprotex Acquires CeeTox II-36
Taconic Announces Name Change II-36
Rosa and Co. Acquires Entelos Holdings' Consulting Service Business II-36
Thermo Fisher Scientific Acquires Life Technologies II-36
AMRI and Ono Pharmaceutical Enter into 5-Year Service Agreement II-37
Xceleron Partners with JCL Bioassay II-37
Taconic Enters into Distribution Agreement with Vivo Bio Tech II-37
Charles River Takes Over Vital River II-37
Taconic and Medicyte Sign Marketing and Sales Agreement II-37
Taconic and InVivos Enter into Distribution Agreement II-37
Simulations Plus Enter into Material Transfer Agreement with
NIEHS II-37
Simulations Plus Collaborates with Bayer HealthCare II-37
QPS Holdings and Hepregen Announce Partnership II-38
Qualyst Transporter Solutions and Hepregen Enter into Co-
Development and Co-Marketing Agreement II-38
Elsevier Takes Over Aureus Sciences II-38
EDSL Purchases Stake in Cerep II-38
Argenta and Antabio Ink Collaboration Agreement II-38
Cyprotex Selects IRIS Accounting Software II-38
Galapagos Creates a New Service Division II-38
Bioreclamation Acquires CelsisIVT II-38
Sigma-Aldrich Acquires Worldwide License for iPS Cell Patent
Portfolio of Kyoto University II-39
Cyprotex and Sigma Life Science Ink Licensing Agreement II-39
Ono Pharmaceutical Enters into an Agreement with BioFocus II-39
Cyprotex Enters into a Collaboration Agreement with Pfizer II-39
Plexpress to Enter into Partnership with SBW II-39
Cyprotex Forms Strategic Alliance with Sirius Analytical
Instruments II-39
WCP Acquires Sterling Reference Laboratories II-39

8. FOCUS ON SELECT PLAYERS II-40
ACEA Biosciences, Inc. (US) II-40
ADMEcell, Inc. (US) II-40
Agilent Technologies, Inc. (US) II-41
Albany Molecular Research, Inc. (US) II-41
Bayer Technology Services GmbH (Germany) II-42
Beckman Coulter, Inc. (US) II-42
BioreclamationIVT, LLC (US) II-43
Cambridge Cell Networks Ltd. (UK) II-43
Cerep SA (France) II-44
CompuDrug International, Inc. (US) II-44
Cyprotex PLC. (UK) II-44
CeeTox, Inc. (US) II-45
Dassault Systemes (France) II-45
Entelos, Inc. (US) II-46
Elsevier B.V. (The Netherlands) II-46
Eurofins ADME BIOANALYSES SAS (France) II-47
Galapagos NV (Belgium) II-47
Molecular Discovery Ltd. (UK) II-48
MultiCASE, Inc. (US) II-48
Optivia Biotechnology (US) II-48
PerkinElmer, Inc. (US) II-49
Pharmaron, Inc. (US) II-49
Promega Corporation (US) II-50
Qualyst, Inc. (US) II-51
Simulations Plus, Inc. (US) II-51
Taconic Farms, Inc. (US) II-51
Takara Bio Europe AB (Sweden) II-52
Tecan Group Ltd. (Switzerland) II-52
Thermo Fisher Scientific, Inc. (US) II-53
Xceleron, Inc. (US) II-54

9. GLOBAL MARKET PERSPECTIVE II-55
Table 11: World Recent Past, Current and Future Analysis for
ADME-Toxicology Testing by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2014 through 2020 (includes corresponding
Graph/Chart) II-55

Table 12: World Historic Review for ADME-Toxicology Testing by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2009 through 2013
(includes corresponding Graph/Chart) II-56

Table 13: World 12-Year Perspective for ADME- Toxicology
Testing by Geographic Region - Percentage Breakdown of
Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest
of World Markets for Years 2009, 2015 and 2020 (includes
corresponding Graph/Chart) II-57

Table 14: World Recent Past, Current and Future Analysis for
Toxicology Testing by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2014 through 2020 (includes corresponding Graph/Chart) II-58

Table 15: World Historic Review for Toxicology Testing by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2009 through 2013
(includes corresponding Graph/Chart) II-59

Table 16: World 12-Year Perspective for Toxicology Testing by
Geographic Region - Percentage Breakdown of Revenues for US,
Canada, Japan, Europe, Asia-Pacific and Rest of World Markets
for Years 2009, 2015 and 2020 (includes corresponding
Graph/Chart) II-60

Table 17: World Recent Past, Current and Future Analysis for
Toxicology Testing by Segment - In-Vivo and In-Vitro
Toxicology Testing Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2014 through 2020
(includes corresponding Graph/Chart) II-61

Table 18: World Historic Review for Toxicology Testing by
Segment - In-Vivo and In-Vitro Toxicology Testing Markets
Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2009 through 2013 (includes corresponding
Graph/Chart) II-62

Table 19: World 12-Year Perspective for Toxicology Testing by
Segment - Percentage Breakdown of Revenues for In-Vivo and
In-Vitro Toxicology Testing Markets for Years 2009, 2015 and
2020 (includes corresponding Graph/Chart) II-63

Table 20: World Recent Past, Current and Future Analysis for
In-Vivo Toxicology Testing by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2014 through 2020 (includes corresponding
Graph/Chart) II-64

Table 21: World Historic Review for In-Vivo Toxicology Testing
by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2009 through 2013
(includes corresponding Graph/Chart) II-65

Table 22: World 12-Year Perspective for In-Vivo Toxicology
Testing by Geographic Region - Percentage Breakdown of
Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest
of World Markets for Years 2009, 2015 and 2020 (includes
corresponding Graph/Chart) II-66

Table 23: World Recent Past, Current and Future Analysis for
In-Vitro Toxicology Testing by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2014 through 2020 (includes corresponding
Graph/Chart) II-67

Table 24: World Historic Review for In-Vitro Toxicology
Testing by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific and Rest of World Markets Independently Analyzed
with Annual Revenue Figures in US$ Million for Years 2009
through 2013 (includes corresponding Graph/Chart) II-68

Table 25: World 12-Year Perspective for In-Vitro Toxicology
Testing by Geographic Region - Percentage Breakdown of
Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest
of World Markets for Years 2009, 2015 and 2020 (includes
corresponding Graph/Chart) II-69

Table 26: World Recent Past, Current and Future Analysis for
ADME Testing by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific and Rest of World Markets Independently Analyzed
with Annual Revenue Figures in US$ Million for Years 2014
through 2020 (includes corresponding Graph/Chart) II-70

Table 27: World Historic Review for ADME Testing by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of
World Markets Independently Analyzed with Annual Revenue
Figures in US$ Million for Years 2009 through 2013 (includes
corresponding Graph/Chart) II-71

Table 28: World 12-Year Perspective for ADME Testing by
Geographic Region - Percentage Breakdown of Revenues for US,
Canada, Japan, Europe, Asia-Pacific and Rest of World Markets
for Years 2009, 2015 and 2020 (includes corresponding
Graph/Chart) II-72


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Clinical Trials Market in the US III-1
Product/Service Launches III-1
Strategic Corporate Developments III-3
Key Players III-6
B.Market Analytics III-16
Table 29: US Recent Past, Current and Future Analysis for
ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and
In-Vitro) and ADME Testing Markets Independently Analyzed
with Annual Revenues in US$ Thousand for Years 2014 through
2020 (includes corresponding Graph/Chart) III-16

Table 30: US Historic Review for ADME-Toxicology Testing by
Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing
Markets Independently Analyzed with Annual Revenues in US$
Thousand for Years 2009 through 2013 (includes corresponding
Graph/Chart) III-17

Table 31: US 12-Year Perspective for ADME- Toxicology
Testing by Segment - Percentage Breakdown of Revenues for
Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets
for Years 2009, 2015 and 2020 (includes corresponding
Graph/Chart) III-18

2. CANADA III-19
Market Analysis III-19
Table 32: Canadian Recent Past, Current and Future Analysis
for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo
and In-Vitro) and ADME Testing Markets Independently
Analyzed with Annual Revenues in US$ Thousand for Years 2014
through 2020 (includes corresponding Graph/Chart) III-19

Table 33: Canadian Historic Review for ADME-Toxicology
Testing by Segment - Toxicology (In-Vivo and In-Vitro) and
ADME Testing Markets Independently Analyzed with Annual
Revenues in US$ Thousand for Years 2009 through 2013
(includes corresponding Graph/Chart) III-20

Table 34: Canadian 12-Year Perspective for ADME-Toxicology
Testing by Segment - Percentage Breakdown of Revenues for
Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets
for Years 2009, 2015 and 2020 (includes corresponding
Graph/Chart) III-21

3. JAPAN III-22
A.Market Analysis III-22
Current and Future Analysis III-22
Strategic Corporate Development III-22
B.Market Analytics III-23
Table 35: Japanese Recent Past, Current and Future Analysis
for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo
and In-Vitro) and ADME Testing Markets Independently
Analyzed with Annual Revenues in US$ Thousand for Years 2014
through 2020 (includes corresponding Graph/Chart) III-23

Table 36: Japanese Historic Review for ADME- Toxicology
Testing by Segment - Toxicology (In-Vivo and In-Vitro) and
ADME Testing Markets Independently Analyzed with Annual
Revenues in US$ Thousand for Years 2009 through 2013
(includes corresponding Graph/Chart) III-24

Table 37: Japanese 12-Year Perspective for ADME-Toxicology
Testing by Segment - Percentage Breakdown of Revenues for
Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets
for Years 2009, 2015 and 2020 (includes corresponding
Graph/Chart) III-25

4. EUROPE III-26
A.Market Analysis III-26
Current and Future Analysis III-26
Clinical Trials Market in Europe III-26
B.Market Analytics III-27
Table 38: European Recent Past, Current and Future Analysis
for ADME-Toxicology Testing by Geographic Region - France,
Germany, Italy, UK, and Rest of Europe Markets Independently
Analyzed with Annual Revenues in US$ Thousand for Years 2014
through 2020 (includes corresponding Graph/Chart) III-27

Table 39: European Historic Review for ADME- Toxicology
Testing by Geographic Region - France, Germany, Italy, UK,
and Rest of Europe Markets Independently Analyzed with
Annual Revenues in US$ Thousand for Years 2009 through 2013
(includes corresponding Graph/Chart) III-28

Table 40: European 12-Year Perspective for ADME-Toxicology
Testing by Geographic Region - Percentage Breakdown of
Revenues for France, Germany, Italy, UK, and Rest of Europe
Markets for Years 2009, 2015 and 2020 (includes corresponding
Graph/Chart) III-29

Table 41: European Recent Past, Current and Future Analysis
for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo
and In-Vitro) and ADME Testing Markets Independently
Analyzed with Annual Revenues in US$ Thousand for Years 2014
through 2020 (includes corresponding Graph/Chart) III-30

Table 42: European Historic Review for ADME- Toxicology
Testing by Segment - Toxicology (In-Vivo and In-Vitro) and
ADME Testing Markets Independently Analyzed with Annual
Revenues in US$ Thousand for Years 2009 through 2013
(includes corresponding Graph/Chart) III-31

Table 43: European 12-Year Perspective for ADME-Toxicology
Testing by Segment - Percentage Breakdown of Revenues for
Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets
for Years 2009, 2015 and 2020 (includes corresponding
Graph/Chart) III-32

4a. FRANCE III-33
A.Market Analysis III-33
Current and Future Scenario III-33
Strategic Corporate Developments III-33
Key Players III-33
B.Market Analytics III-36
Table 44: French Recent Past, Current and Future Analysis for
ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and
In-Vitro) and ADME Testing Markets Independently Analyzed
with Annual Revenues in US$ Thousand for Years 2014 through
2020 (includes corresponding Graph/Chart) III-36

Table 45: French Historic Review for ADME-Toxicology Testing
by Segment - Toxicology (In-Vivo and In-Vitro) and ADME
Testing Markets Independently Analyzed with Annual Revenues
in US$ Thousand for Years 2009 through 2013 (includes
corresponding Graph/Chart) III-37

Table 46: French 12-Year Perspective for ADME-Toxicology
Testing by Segment - Percentage Breakdown of Revenues for
Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets
for Years 2009, 2015 and 2020 (includes corresponding
Graph/Chart) III-38

4b. GERMANY III-39
A.Market Analysis III-39
Current and Future Analysis III-39
Strategic Corporate Development III-39
Bayer Technology Services GmbH - A Key German Player III-39
B.Market Analytics III-40
Table 47: German Recent Past, Current and Future Analysis for
ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and
In-Vitro) and ADME Testing Markets Independently Analyzed
with Annual Revenues in US$ Thousand for Years 2014 through
2020 (includes corresponding Graph/Chart) III-40

Table 48: German Historic Review for ADME- Toxicology
Testing by Segment - Toxicology (In-Vivo and In-Vitro) and
ADME Testing Markets Independently Analyzed with Annual
Revenues in US$ Thousand for Years 2009 through 2013
(includes corresponding Graph/Chart) III-41

Table 49: German 12-Year Perspective for ADME-Toxicology
Testing by Segment - Percentage Breakdown of Revenues for
Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets
for Years 2009, 2015 and 2020 (includes corresponding
Graph/Chart) III-42

4c. ITALY III-43
Market Analysis III-43
Table 50: Italian Recent Past, Current and Future Analysis for
ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and
In-Vitro) and ADME Testing Markets Independently Analyzed
with Annual Revenues in US$ Thousand for Years 2014 through
2020 (includes corresponding Graph/Chart) III-43

Table 51: Italian Historic Review for ADME- Toxicology
Testing by Segment - Toxicology (In-Vivo and In-Vitro) and
ADME Testing Markets Independently Analyzed with Annual
Revenues in US$ Thousand for Years 2009 through 2013
(includes corresponding Graph/Chart) III-44

Table 52: Italian 12-Year Perspective for ADME-Toxicology
Testing by Segment - Percentage Breakdown of Revenues for
Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets
for Years 2009, 2015 and 2020 (includes corresponding
Graph/Chart) III-45

4d. THE UNITED KINGDOM III-46
A.Market Analysis III-46
Current and Future Analysis III-46
Product/Service Launches III-46
Strategic Corporate Developments III-47
Key Players III-48
B.Market Analytics III-50
Table 53: UK Recent Past, Current and Future Analysis for
ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and
In-Vitro) and ADME Testing Markets Independently Analyzed
with Annual Revenues in US$ Thousand for Years 2014 through
2020 (includes corresponding Graph/Chart) III-50

Table 54: UK Historic Review for ADME-Toxicology Testing by
Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing
Markets Independently Analyzed with Annual Revenues in US$
Thousand for Years 2009 through 2013 (includes corresponding
Graph/Chart) III-51

Table 55: UK 12-Year Perspective for ADME- Toxicology
Testing by Segment - Percentage Breakdown of Revenues for
Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets
for Years 2009, 2015 and 2020 (includes corresponding
Graph/Chart) III-52

4e. REST OF EUROPE III-53
A.Market Analysis III-53
Current and Future Analysis III-53
Clinical Trials Market in Select Regions III-53
Russia III-53
Table 56: Russian Clinical Trials Market by Trial Type
(2014): Percentage Breakdown of Number of Trials for
Bioequivalence Studies (Foreign Sponsors), Bioequivalence
Studies (Local Sponsors), Global Multi-Center Clinical
Trials, Local Clinical Trials (Foreign Sponsors), and
Local Clinical Trials (Local Sponsors) (includes
corresponding Graph/Chart) III-53

Table 57: Russian Clinical Trials Market by Hosting
Country (2014): Percentage Breakdown of Trials for
Germany, Russia, Switzerland, United Kingdom, United
States and Others (includes corresponding Graph/Chart) III-54
Spain III-54
Garnering Investments from Multinational Pharma Companies III-54
Table 58: Apportion of R and D Expenditure by Study Phase
in Spain: 2014 (includes corresponding Graph/Chart) III-54
Product/Service Launches III-55
Strategic Corporate Developments III-55
Key Players III-56
B.Market Analytics III-58
Table 59: Rest of Europe Recent Past, Current and Future
Analysis for ADME-Toxicology Testing by Segment - Toxicology
(In-Vivo and In-Vitro) and ADME Testing Markets
Independently Analyzed with Annual Revenues in US$ Thousand
for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-58

Table 60: Rest of Europe Historic Review for ADME-Toxicology
Testing by Segment - Toxicology (In-Vivo and In-Vitro) and
ADME Testing Markets Independently Analyzed with Annual
Revenues in US$ Thousand for Years 2009 through 2013
(includes corresponding Graph/Chart) III-59

Table 61: Rest of Europe 12-Year Perspective for
ADME-Toxicology Testing by Segment - Percentage Breakdown of
Revenues for Toxicology (In-Vivo and In-Vitro) and ADME
Testing Markets for Years 2009, 2015 and 2020 (includes
corresponding Graph/Chart) III-60

5. ASIA-PACIFIC III-61
A.Market Analysis III-61
Current and Future Analysis III-61
Asia: The Most Preferred Destination for Clinical Trials III-61
An Overview of Clinical Trials Market in Select Countries in
the Region III-61
China III-61
Pharmaceutical Outsourcing Sector in China- An Overview III-61
Implementation of GLP Standard Makes Data Internationally
Acceptable III-62
Use of Non-Human Primates- A Key Feature of Chinese
Pharmaceutical Sector III-62
Going Ahead.... III-62
India III-63
A Thriving Clinical Trials Market III-63
Table 62: Cost of Conducting Clinical Trials: India Vs.
US (In US$ Thousand) (includes corresponding Graph/Chart) III-64
Australia III-64
Australia Makes Strong Pitch for Clinical Trials III-64
Major Challenges Facing Australian Clinical Trials Market III-64
Strategic Corporate Developments III-65
B.Market Analytics III-66
Table 63: Asia-Pacific Recent Past, Current and Future
Analysis for ADME-Toxicology Testing by Segment - Toxicology
(In-Vivo and In-Vitro) and ADME Testing Markets
Independently Analyzed with Annual Revenues in US$ Thousand
for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-66

Table 64: Asia-Pacific Historic Review for ADME-Toxicology
Testing by Segment - Toxicology (In-Vivo and In-Vitro) and
ADME Testing Markets Independently Analyzed with Annual
Revenues in US$ Thousand for Years 2009 through 2013
(includes corresponding Graph/Chart) III-67

Table 65: Asia-Pacific 12-Year Perspective for
ADME-Toxicology Testing by Segment - Percentage Breakdown of
Revenues for Toxicology (In-Vivo and In-Vitro) and ADME
Testing Markets for Years 2009, 2015 and 2020 (includes
corresponding Graph/Chart) III-68

6. REST OF WORLD III-69
A.Market Analysis III-69
Current and Future Analysis III-69
Latin America: An Emerging Market for Clinical Trials III-69
The Middle East - Brimming with Potential for Clinical Trials III-69
Table 66: The Middle East Clinical Trial Market (2014):
Percentage Breakdown of Registered Clinical Trials in
Israel, Turkey, Iran, Saudi Arabia, Lebanon, and Rest of
Middle East (includes corresponding Graph/Chart) III-70
B.Market Analytics III-71
Table 67: Rest of World Recent Past, Current and Future
Analysis for ADME-Toxicology Testing by Segment - Toxicology
(In-Vivo and In-Vitro) and ADME Testing Markets
Independently Analyzed with Annual Revenues in US$ Thousand
for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-71

Table 68: Rest of World Historic Review for ADME-Toxicology
Testing by Segment - Toxicology (In-Vivo and In-Vitro) and
ADME Testing Markets Independently Analyzed with Annual
Revenues in US$ Thousand for Years 2009 through 2013
(includes corresponding Graph/Chart) III-72

Table 69: Rest of World 12-Year Perspective for
ADME-Toxicology Testing by Segment - Percentage Breakdown of
Revenues for Toxicology (In-Vivo and In-Vitro) and ADME
Testing Markets for Years 2009, 2015 and 2020 (includes
corresponding Graph/Chart) III-73


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 73 (including Divisions/Subsidiaries - 81)

The United States (48)
Canada (2)
Japan (2)
Europe (24)
- France (4)
- Germany (3)
- The United Kingdom (7)
- Spain (1)
- Rest of Europe (9)
Asia-Pacific (Excluding Japan) (5)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Global Cell-Based Assay Market Growth, Trends & Forecasts(2016 - 2021)

Global Cell-Based Assay Market Growth, Trends & Forecasts(2016 - 2021)

  • $ 4250
  • Industry report
  • August 2016
  • by Mordor Intelligence LLP

The Global Cell based assay Market has been estimated at USD XX billion in 2015 and is projected to reach USD XX billion by 2020, at a CAGR of XX% during the forecast period from 2015 to 2020. Cell-based ...

Outsourcing in Drug Discovery, 7th Edition

Outsourcing in Drug Discovery, 7th Edition

  • $ 4200
  • Industry report
  • April 2016
  • by Kalorama Information

This Kalorama Information study, Outsourcing in Drug Discovery, provides details estimates and forecasts of the contract research organization market and an in depth look into the trends that have shaped ...

Speciality CROs Market, 2016 - 2025

Speciality CROs Market, 2016 - 2025

  • $ 2199
  • Industry report
  • February 2016
  • by Roots Analysis Private Ltd.

INTRODUCTION The biopharmaceutical industry has been witnessing a significant paradigm shift in R&D outsourcing over the last few years. Speciality CROs have emerged as credible players in the market to ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.